Celprogen Introduces Stem Cells In Syringes For In Vivo Applications

Main Category: Stem Cell Research
Article Date: 19 Sep 2008 - 7:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Celprogen Inc., a Global leader in the Stem Cell Research and Therapeutics industry for development of stem cell technologies in regenerative medicine, announced that they have successfully validated shipment of embryonic and adult stem cells at room temperature within United States research facilities for in vivo applications. These Stems including progenitor cells were derived from the following species mouse, rat and human.

Celprogen's stem cells and progenitor cells in the syringes are available for basic science research and drug discovery. The stem cells validated in syringe shipment are as follows: Hepatocytes, Neuronal, Pancreatic, Gastric, Cardiomyocytes, Colon, Lung and Keratinocytes. These stem cells in their syringes are able to maintain their stem-ness and are able to engraft at their organ specific sites once injected within 3 to 5 days from the date shipped. Celprogen has successfully shipped stem cells globally at room temperature in Tissue culture flasks to Asia, Europe and United Kingdom.

Celprogen provides Stem Cell Tissue culture system which includes cells, pre-coated flasks with extracellular matrix and Medium for growth and proliferation of these cells. The stem cell culture system includes stem cell differentiation, expansion and maintaining stem cells in their undifferentiated stage.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing proprietary portfolio of unique cancer therapeutics products and life science research tools that includes stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell products to serve our global community.

Celprogen Inc.